1. Academic Validation
  2. Synthesis, absolute configuration, and molecular modeling study of etoxadrol, a potent phencyclidine-like agonist

Synthesis, absolute configuration, and molecular modeling study of etoxadrol, a potent phencyclidine-like agonist

  • J Med Chem. 1988 Dec;31(12):2257-63. doi: 10.1021/jm00120a004.
A Thurkauf 1 P C Zenk R L Balster E L May C George F I Carroll S W Mascarella K C Rice A E Jacobson M V Mattson
Affiliations

Affiliation

  • 1 Section on Drug Design and Synthesis, National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, Maryland 20892.
Abstract

Etoxadrol (2a), one of the eight possible optical isomers of 2-ethyl-2-phenyl-4-(2-piperidyl)-1,3-dioxolane, was synthesized from (S,S)-1-(2-piperidyl)-1,2-ethanediol, which was obtained from cleavage of dexoxadrol (1a, (S,S)-2,2-diphenyl-4-(2-piperidyl)-1,3-dioxolane). The absolute configuration of etoxadrol hydrochloride, a phencyclidine-like compound biologically, was determined to be 2S, 4S, and 6S at its three chiral centers by single-crystal X-ray analysis. Epietoxadrol (2b), epimeric with etoxadrol at the C-2 center, was also obtained from the synthesis. This much less potent enantiomer has the 2R,4S,6S configuration. The affinity of etoxadrol to the phencyclidine binding site was found to be comparable to that of phencyclidine itself and was 35 times more potent than its epimer, epietoxadrol. Three diastereomeric mixtures were prepared that had low affinity for the phencyclidine site. In studies of the discriminative stimulus properties of these compounds, it was found that only etoxadrol substituted for the phencyclidine stimulus. With use of computer-assisted molecular modeling techniques, a hypothetical phencyclidine binding site model has been developed that, unlike our former hypothesis based on Dreiding models, correctly predicts the higher affinity of etoxadrol and the lesser affinity of epietoxadrol for the phencyclidine site.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-107040
    NMDA Antagonist